Dr. Lin-Arlow is co-founder and CEO of Ansa Biotechnologies. He grew the company from a team of 2 people in 2018 to 86 people currently, raising over $86M in venture capital and grants to fund the company’s development. Dan received his PhD from the University of California, Berkeley for his work in Jay Keasling’s lab developing innovative technologies for the de novo synthesis of DNA. Prior to graduate school, he was a Scientific Associate at D.E. Shaw Research where he studied the biophysical properties of G protein-coupled receptors, including how drugs bind and modulate their activity. Dan began his scientific career at MIT, where he earned dual S.B. degrees in Math with Computer Science and Biology, and developed computation tools for the analysis of regulation of gene expression at the Broad Institute of MIT and Harvard. He has co-authored over twenty scientific publications, including papers in Nature, Science, Cell, PNAS, and Nature Biotechnology that have been cited over 8,500 times in aggregate, and is a co-inventor of 9 patents families.